MRI Detection of Microbleeds in Glioma Patients

Systematic retrospective medical chart and medical imaging file review of all patients receiving brain MRI for the follow-up of glioblastoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Glioblastoma Astrocytoma Glioma Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Neoplasms, Neuroepithelial Neuroectodermal Tumors

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patients
Diagnosed with brain glioblastoma
Receiving treatment with cranial radiotherapy and/or chemotherapy
Having at least one follow-up MRI conducted that used a susceptibility weighted imaging sequence

Exclusion criteria

Underage
Absence of formal diagnosis of glioblastoma
No available medical imaging file with MRI susceptibility weighted imaging sequence

Treatment and study plan

Primary outcomes

Number of microbleeds diagnosed with MRI (susceptibility weighted imaging sequence)

Time frame: At the time of each MRI conducted within 5 years after diagnosis

Sponsors and collaborators

Lead sponsor

Fondation Ophtalmologique Adolphe de Rothschild

Network

Registry information

Official study title

Detection of Microbleeds With MRI (SWI Sequences) in Glioma Patients

Acronym: SWIGLI

Important dates

Study start: 2015
Primary completion: 2015
First posted: Sep 14, 2016
Registry last updated: Sep 14, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed